[1]
|
Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastro-enterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Hepatology, 55, 2005-2023.
doi:10.1002/hep.25762
|
[2]
|
Ekstedt, M., Franzén, L.E., Mathiesen, U.L., et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 44, 865-873.
doi:10.1002/hep.21327
|
[3]
|
Yoshiji, H., Kuriyama, S., Yoshii, J., et al. (2001) Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 34, 745-750. doi:10.1053/jhep.2001.28231
|
[4]
|
Gaedeke, J., Peters, H., Noble, N.A. and Border, W.A. (2001) Angiotensin II, TGF-beta and renal fibrosis. Contributions to Nephrology, 135, 153-160.
doi:10.1159/000060162
|
[5]
|
Nagy, P., Scaff, Z. and Lapis K. (1991) Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology, 14, 269-273.
doi:10.1002/hep.1840140211
|
[6]
|
Matsuoka, M. and Tsukamoto, H. (1990) Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: Implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology, 11, 599-605. doi:10.1002/hep.1840110412
|
[7]
|
Nagy, P., Scaff, Z. and Lapis, K. (1991) Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology, 14, 269-273.
doi:10.1002/hep.1840140211
|
[8]
|
Yokohama, S., Yoneda, M., Haneda, M., et al. (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology, 40, 1222-1225. doi:10.1002/hep.20420
|
[9]
|
Mizuno, M., Sada, T., Ikeda, M., et al. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. European Journal of Pharmacology, 285, 181-188. doi:10.1016/0014-2999(95)00401-6
|
[10]
|
Oparil, S., Williams, D., Chrysant, S.G., Marbury, T.C. and Neutel, J. (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. Journal of Clinical Hypertension (Greenwich), 3, 283-291.
doi:10.1111/j.1524-6175.2001.01136.x
|
[11]
|
Hirose, A., Ono, M., Saibara, T., et al. (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 45, 1375-1381.
doi:10.1002/hep.21638
|
[12]
|
Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 13131321. doi:10.1002/hep.20701
|
[13]
|
Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A. and Bacon, B.R. (1999) Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. American Journal of Gastroenterology, 94, 2467-2474.
doi:10.1111/j.1572-0241.1999.01377.x
|
[14]
|
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
doi:10.1007/BF00280883
|
[15]
|
Hamaguchi, M., Kojima, T., Takeda, N., et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine, 143, 722-728.
doi:10.7326/0003-4819-143-10-200511150-00009
|
[16]
|
Torres, D.M., Jones, F.J., Shaw, J.C., Williams, C.D., Ward, J.A. and Harrison, S.A. (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open-label trial. Hepatology, 54, 1631-1639.
doi:10.1002/hep.24558
|
[17]
|
Sanyal, A.J., Chalasini, N., Kowdley, K.V., et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine, 362, 16751685. doi:10.1056/NEJMoa0907929
|
[18]
|
Aithal, G.P., Thomas, J.A. and Kaye, P.V. (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 135, 1176-1184.
doi:10.1053/j.gastro.2008.06.047
|
[19]
|
Belfort, R., Harrison, S.A., Brown, K., et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine; 355, 2297-2307. doi:10.1056/NEJMoa060326
|
[20]
|
Ratziu, V., Giral, P., Jacqueminet, S., et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology, 135, 100-110.
doi:10.1053/j.gastro.2008.03.078
|
[21]
|
Hidaka, H., Nakazawa, T., Shibuya, A., et al. (2011) Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: A randomized controlled trial. Journal of Gastroenterology, 46, 1316-1323. doi:10.1007/s00535-011-0449-z
|
[22]
|
Jin, H., Yamamoto, N., Uchida, K., Terai, S. and Sakaida, I. (2007) Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochemical and Biophysical Research Communications, 364, 801807. doi:10.1016/j.bbrc.2007.10.083
|
[23]
|
Fujita, K., Yoneda, M., Wada, K., et al. (2007) Telmisartan, angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digestive Diseases Sciences, 52, 3455-3464.
doi:10.1007/s10620-007-9741-4
|
[24]
|
Yoshida, T., Yamagishi, S., Matsui, T., et al. (2008) Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. Journal of International Medical Research, 36, 237-243.
doi:10.1177/147323000803600204
|